Home>Topics>Stocks>Progenics Pharmaceuticals

Progenics Pharmaceuticals PGNX

  1. All
  2. Commentary
  3. Headlines
    1. Investor or Speculator?

      Headlines

      Tue, 12 Aug 2014

      Progenics Pharmaceuticals PGNX and partner Wyeth WYE announced Thursday that both the Food and Drug Administration and the European Medicines Agency have accepted

    2. It’s Never Too Early: Roth 401(k)s and Other Fun Stuff

      Headlines

      Thu, 3 Apr 2014

      Progenics Pharmaceuticals PGNX announced on March 6 that it would backtrack and reformulate the oral version opioid bowel dysfunction drug MNTX to make it more

    3. Shares of Salix, Progenics drop after FDA rejects drug

      Headlines

      Mon, 30 Jul 2012

      (Reuters) - Shares of Salix Pharmaceuticals Ltd and Progenics Pharmaceuticals tumbled after U.S. health regulators declined to approve wider use of their drug for opioid-induced constipation and...

    4. Dropping Coverage of Progenics Pharmaceuticals

      Commentary

      Tue, 6 Sep 2011

      We are no longer providing equity research on Progenics Pharmaceuticals PGNX . We provide broad coverage of more than 1,700 companies across more than 140 industries, and adjust our coverage as necessary based on client demand and investor interest.

    5. Dropping Coverage of Progenics Pharmaceuticals

      Commentary

      Wed, 5 Jan 2011

      We're dropping coverage of Progenics Pharmaceuticals PGNX to focus our resources elsewhere.

    6. Progenics Extends Agreement with Wyeth

      Commentary

      Tue, 28 Sep 2010

      Progenics Pharmaceuticals PGNX announced that it extended its domestic commercialization agreement with former partner Wyeth (now part of Pfizer PFE) by three

    7. Progenics Still Without Partner

      Commentary

      Wed, 30 Jun 2010

      Progenics Pharmaceuticals PGNX reported first-quarter earnings that were slightly lower than we expected, but we are holding on to our probability-weighted

    8. 2010 Preview for Progenics

      Commentary

      Wed, 27 Jan 2010

      We are maintaining our fair value estimate for Progenics PGNX , as no deals have transpired to affect our probability-weighted scenarios for the firm. The firm brought research and development

    9. Progenics Regains Rights to Relistor

      Commentary

      Wed, 14 Oct 2009

      Progenics Pharmaceuticals PGNX announced Wednesday that it has regained worldwide rights to the Relistor franchise from its partner Wyeth WYE (soon to be acquired

    10. Losses Continue for Progenics

      Commentary

      Thu, 6 Aug 2009

      Progenics Pharmaceuticals ' PGNX revenue for the second quarter came in slightly below our expectations, but this doesn't change our long-term outlook. We

    « Prev1234Next »
    Content Partners